CLC_Case_Study_4.docx CLC-Case Study 4 HLT-411 CLC-Case Study 4 Rates of cervical cancer are much higher in developed countries due to their lack of resources and shortage of screening programs that are high qual
...
CLC_Case_Study_4.docx CLC-Case Study 4 HLT-411 CLC-Case Study 4 Rates of cervical cancer are much higher in developed countries due to their lack of resources and shortage of screening programs that are high quality and produce results, but still cost-effective so countries can afford them (Baker, 2009). In fact, around 85% of all deaths related to cervical cancer are in low-income and low-resource areas, only proving that these countries need solutions more than ever (Baker, 2009). High mortality rates can be connected to social determinant of the people in area, whether that be mitrust of the government aid or even social stereotypes for the people in the area like not needing a PAP smear. Segregation and racial differences can also be a determinant. In terms of economic determinants, inadequate resources, technology, and money can lead to areas not having any way to test citizens, or even not enough education to know how to test and use the technology. Lastly, cultural determinants include cultural practice. In some cultures, it may be frowned upon to see a doctor or have tests done like a PAP smear. Many cultures also only follow their own holistic treatments, and would not want treatment through a hospital or medication. New technologies allow alternate screen methods that could help overcome many different obstacles. Screening has been much less successful in developing regions. Certain conditions must be in place for these new prevention technologies to become available and be effe. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . .. .. . . . . . . . . . . . . . . . . . .. . . . .
[Show More]